At the 2019 OncLive®
State of the Science Summit™
on Breast Cancer, experts from West Cancer Center highlighted the exciting research being conducted at their institution.
Lee Schwartzberg, MD, FACP: Executive Director and Medical Director, West Cancer Center; Chief and Professor of Medicine, Division of Hematology/Oncology, University of Tennessee Health Science Center; Chief Medical Officer, OneOncology
Lee Schwartzberg, MD, FACP
“We are doing a number of trials at West Cancer Center with immunotherapy. One interesting trial is examining an oral taxane called tesetaxel, which is given once every 3 weeks. A registration trial (NCT03858972) that has just completed accrual [is examining tesetaxel] in combination with capecitabine versus capecitabine alone in [patients with] hormone receptor–positive, HER2-negative breast cancer. We should see the results of that study in 2020.